SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

VOLUNTARY ANNOUNCEMENT – ACCEPTANCE OF THE NEW DRUG APPLICATION FOR ROCONKIBART INJECTION

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the "**Company**") on a voluntary basis. Reference is also made to the overseas regulatory announcement of the Company dated 5 December 2025.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the Company has received the Acceptance Notice (《受理通知書》) issued by the National Medical Products Administration recently. The new drug application (the "**NDA**") for the Company's product, roconkibart injection (a recombinant humanized anti-IL-17A monoclonal antibody injection, product code: JS005), for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy has been accepted.

ABOUT ROCONKIBART INJECTION

Drug name: Roconkibart Injection
Application matter: Registration of Domestic Production of Pharmaceutical Product
Acceptance Nos.: CXSS2500129, CXSS2500130
Specification: 150 mg (1 ml) in a single dose (pre-filled syringe), 150 mg (1 ml) in a single dose (pre-filled autosyringe)
Review conclusion: It is decided to be accepted upon review according to the requirements of Article 32 of the Administrative License Law of the People's Republic of China* (《中華人民共和國行政許可法》).

Roconkibart is a specific anti-IL-17A monoclonal antibody independently developed by the Company. IL (interleukin)-17A is a pleiotropic cytokine, and the disordered secretion of which is closely related to the occurrence and progression of autoimmune diseases such as psoriasis, rheumatoid arthritis and ankylosing spondylitis. By binding to IL-17A with high affinity and selectively blocking the binding of IL-17A with its receptor IL-17RA/IL-17RC, roconkibart blocks the activation of downstream signaling pathways and the release of inflammatory factors, thereby effectively alleviating the symptoms of autoimmune diseases. As at the date of this announcement, on top of the filing for the NDA, all subjects in the phase II clinical study of roconkibart for the treatment of active ankylosing spondylitis have completed the treatment and entered the safe follow-up period.

Psoriasis is a common chronic, recurrent, inflammatory, and systemic disease mediated by the immune system. According to the Guideline for the Diagnosis and Treatment of Psoriasis in China (2023 edition), the prevalence of psoriasis in China reached 0.47% in 2008, significantly higher than the 0.12% recorded in 1984. Psoriasis can be accompanied by other systemic abnormalities, and patients with moderate to severe psoriasis have an increased risk of developing metabolic syndrome and atherosclerotic cardiovascular disease. Mental health conditions such as depression, anxiety, and suicidal tendencies caused by physical and psychological distress are also relatively common among the patients with psoriasis. Therefore, psoriasis is a disease that seriously affects the physical and mental health of patients.

The NDA is mainly based on the multi-center, randomized, double-blind, parallel and placebo-controlled pivotal registrational phase III clinical study (study number: JS005-005-III-PsO). Led by Professor Zhang Jianzhong* (張建中) from the Peking University People's Hospital* (北京大學人民醫院), the study was conducted in 60 clinical sites across China, and a total of 747 patients with moderate to severe plaque psoriasis were enrolled.

The study results showed that, treatment with roconkibart for 12 weeks significantly improved the Psoriasis Area and Severity Index (PASI) of 75/90/100 and the static Physician Global Assessment (sPGA) score of 0 or 1. The efficacy was significantly superior to that of the placebo group and remained stable throughout the 52-week treatment, with an overall favorable safety profile. The relevant study results will be announced at future international academic conferences.

RISK WARNING

Due to the high-tech, high-risk, and high value-added characteristics of pharmaceutical products, there are significant risks and uncertainties in the research, development, and commercialization processes of drugs. These multiple stages are susceptible to various uncertain factors. Investors are advised to make cautious decisions and pay careful attention to investment risks. The Company will actively pursue the described project and fulfill its information disclosure obligations in a timely manner for subsequent progress in strict compliance with relevant regulations.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 5 December 2025

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Yao Sheng, Dr. Wang Gang and Dr. Li Xin as executive Directors; Mr. Tang Yi as a non-executive Director; and Mr. Zhang Chun, Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun and Dr. Yang Jin as independent non-executive Directors.

* *For identification purposes only*